605 related articles for article (PubMed ID: 28822825)
1. Comparison of transforaminal lumbar interbody fusion outcomes in patients receiving rhBMP-2 versus autograft.
Khan TR; Pearce KR; McAnany SJ; Peters CM; Gupta MC; Zebala LP
Spine J; 2018 Mar; 18(3):439-446. PubMed ID: 28822825
[TBL] [Abstract][Full Text] [Related]
2. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 2: BMP dosage-related complications and long-term outcomes in 509 patients.
Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R
Spine (Phila Pa 1976); 2013 Jun; 38(13):1137-45. PubMed ID: 23354111
[TBL] [Abstract][Full Text] [Related]
3. RhBMP-2-induced radiculitis in patients undergoing transforaminal lumbar interbody fusion: relationship to dose.
Villavicencio AT; Burneikiene S
Spine J; 2016 Oct; 16(10):1208-1213. PubMed ID: 27343729
[TBL] [Abstract][Full Text] [Related]
4. Clinical sequelae after rhBMP-2 use in a minimally invasive transforaminal lumbar interbody fusion.
Singh K; Nandyala SV; Marquez-Lara A; Cha TD; Khan SN; Fineberg SJ; Pelton MA
Spine J; 2013 Sep; 13(9):1118-25. PubMed ID: 24029138
[TBL] [Abstract][Full Text] [Related]
5. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 1: Large series diagnosis related outcomes and complications with 2- to 9-year follow-up.
Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R
Spine (Phila Pa 1976); 2013 Jun; 38(13):1128-36. PubMed ID: 23370679
[TBL] [Abstract][Full Text] [Related]
6. Nerve injury and recovery after lateral lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a cohort-controlled study.
Lykissas MG; Aichmair A; Sama AA; Hughes AP; Lebl DR; Cammisa FP; Girardi FP
Spine J; 2014 Feb; 14(2):217-24. PubMed ID: 24269858
[TBL] [Abstract][Full Text] [Related]
7. Complications associated with single-level transforaminal lumbar interbody fusion.
Rihn JA; Patel R; Makda J; Hong J; Anderson DG; Vaccaro AR; Hilibrand AS; Albert TJ
Spine J; 2009 Aug; 9(8):623-9. PubMed ID: 19482519
[TBL] [Abstract][Full Text] [Related]
8. Comparison of TLIF with rhBMP-2 versus no TLIF and higher posterolateral rhBMP-2 dose at L5-S1 for long fusions to the sacrum with sacropelvic fixation in patients with primary adult deformity.
Rahman RK; Buchowski JM; Stephens B; Dorward IG; Koester LA; Bridwell KH
Spine (Phila Pa 1976); 2013 Dec; 38(26):2264-71. PubMed ID: 24108280
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of recombinant human bone morphogenetic protein-2 versus local bone graft in primary lumbar interbody fusions.
Adams CL; Ogden K; Robertson IK; Broadhurst S; Edis D
Spine (Phila Pa 1976); 2014 Jan; 39(2):164-71. PubMed ID: 24153173
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic morphogenetic protein vs. recombinant human bone morphogenetic protein-2 in lumbar interbody fusion procedures: a radiographic and economic analysis.
Roh JS; Yeung CA; Field JS; McClellan RT
J Orthop Surg Res; 2013 Dec; 8():49. PubMed ID: 24373225
[TBL] [Abstract][Full Text] [Related]
11. Prospective, randomized, controlled trial of silicate-substituted calcium phosphate versus rhBMP-2 in a minimally invasive transforaminal lumbar interbody fusion.
Nandyala SV; Marquez-Lara A; Fineberg SJ; Pelton M; Singh K
Spine (Phila Pa 1976); 2014 Feb; 39(3):185-91. PubMed ID: 24253788
[TBL] [Abstract][Full Text] [Related]
12. A comparison of radiographic and clinical outcomes of anterior lumbar interbody fusion performed with either a cellular bone allograft containing multipotent adult progenitor cells or recombinant human bone morphogenetic protein-2.
Lee DD; Kim JY
J Orthop Surg Res; 2017 Aug; 12(1):126. PubMed ID: 28841904
[TBL] [Abstract][Full Text] [Related]
13. Radiographic Appearance of Transforaminal Lumbar Interbody Fusion Performed With and Without Recombinant Human Morphogenetic Protein-2.
Stensby JD; Kaliney RW; Alford B; Shen FH; Patrie JT; Fox MG
AJR Am J Roentgenol; 2016 Mar; 206(3):588-94. PubMed ID: 26901016
[TBL] [Abstract][Full Text] [Related]
14. Symptomatic ectopic bone formation after off-label use of recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion.
Chen NF; Smith ZA; Stiner E; Armin S; Sheikh H; Khoo LT
J Neurosurg Spine; 2010 Jan; 12(1):40-6. PubMed ID: 20043763
[TBL] [Abstract][Full Text] [Related]
15. A Systematic Review of Lumbar Fusion Rates With and Without the Use of rhBMP-2.
Galimberti F; Lubelski D; Healy AT; Wang T; Abdullah KG; Nowacki AS; Benzel EC; Mroz TE
Spine (Phila Pa 1976); 2015 Jul; 40(14):1132-9. PubMed ID: 25955186
[TBL] [Abstract][Full Text] [Related]
16. Does recombinant human bone morphogenetic protein-2 use in adult spinal deformity increase complications and are complications associated with location of rhBMP-2 use? A prospective, multicenter study of 279 consecutive patients.
Bess S; Line BG; Lafage V; Schwab F; Shaffrey CI; Hart RA; Boachie-Adjei O; Akbarnia BA; Ames CP; Burton DC; Deverin V; Fu KM; Gupta M; Hostin R; Kebaish K; Klineberg E; Mundis G; O'Brien M; Shelokov A; Smith JS;
Spine (Phila Pa 1976); 2014 Feb; 39(3):233-42. PubMed ID: 24477081
[TBL] [Abstract][Full Text] [Related]
17. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages.
Haid RW; Branch CL; Alexander JT; Burkus JK
Spine J; 2004; 4(5):527-38; discussion 538-9. PubMed ID: 15363423
[TBL] [Abstract][Full Text] [Related]
18. Bone morphogenetic protein use in spine surgery in the United States: how have we responded to the warnings?
Guzman JZ; Merrill RK; Kim JS; Overley SC; Dowdell JE; Somani S; Hecht AC; Cho SK; Qureshi SA
Spine J; 2017 Sep; 17(9):1247-1254. PubMed ID: 28456674
[TBL] [Abstract][Full Text] [Related]
19. Complications of rhBMP-2 utilization for posterolateral lumbar fusions requiring reoperation: a single practice, retrospective case series report.
Hoffmann MF; Jones CB; Sietsema DL
Spine J; 2013 Oct; 13(10):1244-52. PubMed ID: 23973099
[TBL] [Abstract][Full Text] [Related]
20. Dose Adjustment Associated Complications of Bone Morphogenetic Protein: A Longitudinal Assessment.
De Stefano FA; Elarjani T; Burks JD; Burks SS; Levi AD
World Neurosurg; 2021 Dec; 156():e64-e71. PubMed ID: 34530148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
